Lecture 54-57 - Pharmacotherapy of Schizophrenia Flashcards
Key features that define psychotic disorders:
- Delusions – fixed false beliefs that are not amenable to change even with conflicting evidence
- Hallucinations – perception-like experiences that occur without an external stimulus (usually auditory, but can also be visual, tactile, or olfactory)
- Disorganized thinking and speech – switching from one topic to another, unrelated answers to questions
- Disorganized or abnormal motor behavior
- Negative symptoms
Disease Course in Schizophrenia
Onset late adolescence to early adulthood
Men – late teens, early 20’s
Women – late 20’s, early 30’s
Link to Substance Use
Smoking is associated with induction of 1A2, not due to nicotine, but because of hydrocarbons produced and inhaled, which decreases the serum concentration of 1A2 substrate antipsychotics (olanzapine, asenapine, clozapine, loxapine)
Marijuana, cocaine, and amphetamine use can hasten the onset of schizophrenia, exacerbate symptoms, and reduce time to relapse
Substance use treatment can be successfully achieved along with mental health treatment in patients with schizophrenia, should be undertaken at the same time
Antipsychotic Drug Therapy Overview
MUST CONSIDER:
◦ Doses per day
◦ Side effects – what will the patient tolerate? What are their other disease states or risk factors?
◦ Previous drug therapy – success or failure? Do family members have this disease? What did they take?
◦ Cost of drug therapy – How will the patient pay for it? Oral or Intramuscular depot?
◦ Concomitant drug therapy
◦ Need for monitoring – labs? Weight? ECG?
Antipsychotic Drug Selection
Oral antipsychotic drug therapy is generally considered first-line, unless the patient presents with reasons to consider IM depot drug therapy first
Typical Antipsychotics
◦ Older agents – primarily D2 receptor antagonists
◦ Efficacy for positive symptoms is similar to atypical antipsychotics
Haloperidol, Fluphenazine, Loxapine, Chlorpromazine, perphenazine, thioridazine
Typical Antipsychotics Clinical Pearls
◦ Haloperidol is most commonly used – routine and PRN
◦ More EPS with higher potency typicals
◦ Are very effective for treating the positive
symptoms, but are likely to worsen negative
and cognitive symptoms
Atypical Antipsychotics
◦ D2 antagonists + 5HT2A antagonists
◦ Less EPS than typicals; more metabolic side effects
Aripiprazole, Clozapine, Olanzapine, Ziprasidone, Asenapine, Iloperidone, Paliperidone, Brexpiprazole, Lumateperone, Quetiapine, Cariprazine, Lurasidone, Risperidone
Partial Agonists
◦ “Stabilize” dopamine transmission – not too much, not too little
◦ Associated with more akathisia than other antipsychotics
◦ Approved for adjunct treatment in depression so all have boxed warning for suicidal thoughts/behavior
aripiprazole, brexpiprazole, cariprazine
Aripiprazole
- 2D6 and 3A4 substrate
- Moderate akathisia
- Low weight gain
Brexpiprazole
- 2D6 and 3A4 substrate
- Moderate akathisia
- Low-moderate weight gain
Cariprazine
- 3A4 substrate
- Moderate akathisia
- Low-moderate weight gain
The “Pines”
◦ Less D2 antagonism, more 5HT2A antagonist – so significantly less EPS
◦ Higher weight gain than other agents
asenapine, clozapine, olanzapine, quetiapine
Asenapine
- Sublingual and
patch formulations - 1A2 substrate
- QTc prolongation
Clozapine
1A2 substrate
* Boxed warnings:
neutropenia, orthostasis, bradycardia, syncope, seizures, myocarditis, cardiomyopathy
* Side effects: sedation,
weight gain, constipation, hypersalivation, dry
mouth, GI hypomotility
with obstruction risk
* QTc prolongation
Olanzapine
- 1A2 substrate
- Significant weight gain and sedation
- High risk metabolic syndrome
- DRESS warning
Quetiapine
- 3A4 substrate
- QTc prolongation
- Weight gain and sedation
- Boxed warning for suicidal ideation
Asenapine Transdermal Patch (Secuado®)
Apply one patch every 24 hours, rotate patch site to minimize application site reactions
Warnings for QTc prolongation
UGT and 1A2 substrate – reduce dose of patch if given with strong 1A2 inhibitors (e.g., fluvoxamine)
Clozapine REMS
Reduces ANC to 1500/μL to initiate therapy; monitoring timelines weekly x 6 months, biweekly x 6 months, then every 4 weeks
Olanzapine/Samidorphan (Lybalvi®)
◦ Samidorphan is an opioid antagonist with preferential activity at the mu opioid receptor
samidorphan added to mitigate weight gain
do not take if pt already on opioids
The “Dones”
◦ D2 and 5HT2A antagonists
◦ Variable EPS and metabolic side effects
Iloperidone
lurasidone
ziprasidone
Iloperidone
- High risk for orthostasis and syncope
- QTc prolongation
- 2D6 substrate